Drug Supply Chain Security Act (DSCSA): 2023 Update for Pharmacy Post-test | April 24, 2023 - April 23, 2026

The Drug Supply Chain Security Act is designed to:*
- Prevent illegitimate products from entering the US Pharmaceutical Supply Chain
- Prevent suspect raw ingredients from entering the US Pharmaceutical Supply Chain
- Prevent the sale of expired products from entering the US Pharmaceutical Supply Chain
- All of the above
The Pharmacy needs to validate the authorized training partners (ATPs) it obtains products from by:*
- Validating the wholesaler license with the State or FDA for Manufacturers
- Obtain a written agreement from the ATP
- Ensure the ATP has a physical warehouse within your State
- All of the above
Which of the following is not part of the Product Identifier?*
- Serial number
- Wholesaler/Manufacturer Order Number
- NDC
- Lot Number
Which of the following is not currently part of the required part of transaction data?*
- Transaction History
- Transaction Information
- Transaction Statement
- Transaction Processor
The Transaction Information must include the Product identifier (Serial Number, NDC, Lot Number, and Expiration Date) on and beyond 11/27/2023.*
- True
- False
By 11/27/2023, the Enhanced Drug Distribution Security (EDDS) section of DSCSA requires Authorized Trading Partners to send the Transaction Data (Transaction Information and Transaction Statement) to the Pharmacy via what method?*
- PDF
- Email and include with the shipping containers
- Electronic, secure, and interoperable format
- On an online portal maintained by the wholesaler or manufacturer
How long must The Transaction Data (transaction information, transaction statement, and transaction history) be kept?*
- 3 years
- 5 years
- 6 Years
- 7 Years
If a Pharmacy believes they have a suspect product, what must they do to comply with DSCSA?*
- Quarantine the Product and conduct an investigation with the assistance of the ATP purchased from and the manufacturer to determine the legitimacy
- Immediately return the Product to the ATP the Product was purchased from
- Send the Product back to the manufacturer
- Set the Product aside for return to a reverse distributor
If a product is determined to be suspect, the Pharmacy must?*
- Immediately return the Product to the ATP the Product was purchased from
- Send the Product back to the manufacturer
- Set the Product aside for return to a reverse distributor
- Notify the FDA via the FDA Form 3911, and wait for instructions from the FDA on handling the illegitimate Product.
A Pharmacy may only sell products to another pharmacy if?*
- They share common ownership
- The Product to for a specific patient's prescription
- To get rid of overstock to a Pharmacy that does not share common ownership
- a and b only

Drug Supply Chain Security Act (DSCSA): 2023 Update for Pharmacy Post-test | April 24, 2023 – April 23, 2026

Step 1 of 2

Drug Supply Chain Security Act (DSCSA): 2023 Update for Pharmacy Post-test | April 24, 2023 – April 23, 2026

Step 1 of 2

Join our newsletter